Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Toll-Free Number for Consumer Reporting of Drug Product Side Effects: Comprehension, 57951 [E7-20075]
Download as PDF
Federal Register / Vol. 72, No. 196 / Thursday, October 11, 2007 / Notices
In the Federal Register of July 9, 2007
(72 FR 37242), FDA published a 60-day
notice requesting public comment on
the information collection provisions.
No comments were received.
Dated: October 4, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7–20070 Filed 10–10–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Quality System Regulation Educational
Forum on Design Controls; Public
Workshop
AGENCY:
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0036]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Toll-Free Number for Consumer
Reporting of Drug Product Side
Effects: Comprehension
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Toll-Free Number for Consumer
Reporting of Drug Product Side Effects:
Comprehension’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Karen L. Nelson, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4816.
In the
Federal Register of February 2, 2007 (72
FR 5056), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0603. The
approval expires on January 31, 2008. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
rwilkins on PROD1PC63 with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: October 4, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7–20075 Filed 10–10–07; 8:45 am]
BILLING CODE 4160–01–S
VerDate Aug<31>2005
16:09 Oct 10, 2007
Jkt 214001
Food and Drug Administration,
HHS.
Notice of public workshop.
SUMMARY: The Food and Drug
Administration (FDA), Office of
Regulatory Affairs, Southwest Region,
Dallas District Office, in collaboration
with the FDA Medical Device Industry
Coalition (FMDIC), is announcing a
public workshop entitled ‘‘Quality
System Regulation Educational Forum
on Design Controls.’’ This public
workshop is intended to provide
information about FDA’s Medical
Device Quality Systems Regulation
(QSR) to the regulated industry,
particularly small businesses.
Date and Time: The public workshop
will be held on April 4, 2008, from 8
a.m. to 5 p.m.
Location: The public workshop will
be held at the Omni Mandalay Hotel at
Las Colinas, 221 East Las Colinas Blvd.,
Dallas (Irving), TX 75039. Directions to
the facility are available at the FMDIC
Web site at https://www.fmdic.org/.
Contact Person: David Arvelo, Food
and Drug Administration, 4040 North
Central Expressway, suite 900, Dallas,
TX 75204, 214–253–4952, FAX: 214–
253–4970, e-mail
david.arvelo@fda.hhs.gov.
Registration: FMDIC has a $250 early
registration fee. Early registration ends
March 21, 2008. Registration is $350
thereafter. To register online, please
visit https://www.fmdic.org/. As an
alternative, you may send registration
information including name, title, firm
name, address, telephone and fax
numbers, and e-mail, along with a check
or money order for the appropriate
amount payable to the FMDIC, to Dr.
William Hyman, Texas A&M University,
Department of Biomedical Engineering,
3120 TAMU, College Station, TX
75843–3120. Registration onsite will be
accepted on a space available basis on
the day of the public workshop
beginning at 8 a.m. The cost of
registration at the site is $350 payable to
the FMDIC. The registration fee will be
used to offset expenses of hosting the
event, including meals, refreshments,
meeting rooms, and materials.
If you need special accommodations
due to a disability, please contact David
Arvelo (see Contact Person) at least 21
days in advance.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
57951
Transcripts: Transcripts of this event
will not be available due to the format
of this workshop. Event handouts may
be requested in writing from the
Freedom of Information Office (HFI–35),
Food and Drug Administration, 5600
Fishers Lane, rm. 6–30, Rockville, MD
20857, approximately 15 working days
after the public workshop at a cost of 10
cents per page.
The
workshop is being held in response to
the interest in the topics discussed from
small medical device manufacturers in
the Dallas District area. FMDIC and FDA
present this workshop to help achieve
objectives set forth in section 406 of the
Food and Drug Administration
Modernization Act of 1997 (21 U.S.C.
393), which include working closely
with stakeholders and maximizing the
availability and clarity of information to
stakeholders and the public. This is also
consistent with the purposes of FDA’s
Regional Small Business Program,
which are in part to respond to industry
inquiries, develop educational
materials, sponsor workshops and
conferences to provide firms,
particularly small businesses, with
firsthand working knowledge of FDA’s
requirements and compliance policies.
This workshop is also consistent with
the Small Business Regulatory
Enforcement Fairness Act of 1996
(Public Law 104–121), as an outreach
activity by Government agencies to
small businesses.
The goal of the workshop is to present
information that will enable
manufacturers and regulated industry to
better comply with the Medical Device
QSR. The following topics will be
discussed at the workshop: (1) Planning
design controls, (2) design inputs and
outputs, (3) design validation and
verification, (4) design transfer and
change, (5) control of suppliers, (6)
design history file, and (7) how design
controls relate to corrective and
preventive action, change control, and
risk management.
SUPPLEMENTARY INFORMATION:
Dated: October 4, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–20077 Filed 10–10–07; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\11OCN1.SGM
11OCN1
Agencies
[Federal Register Volume 72, Number 196 (Thursday, October 11, 2007)]
[Notices]
[Page 57951]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20075]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0036]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Toll-Free Number for Consumer
Reporting of Drug Product Side Effects: Comprehension
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Toll-Free Number for Consumer
Reporting of Drug Product Side Effects: Comprehension'' has been
approved by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of the Chief
Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-4816.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 2, 2007
(72 FR 5056), the agency announced that the proposed information
collection had been submitted to OMB for review and clearance under 44
U.S.C. 3507. An agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it displays
a currently valid OMB control number. OMB has now approved the
information collection and has assigned OMB control number 0910-0603.
The approval expires on January 31, 2008. A copy of the supporting
statement for this information collection is available on the Internet
at https://www.fda.gov/ohrms/dockets.
Dated: October 4, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-20075 Filed 10-10-07; 8:45 am]
BILLING CODE 4160-01-S